PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Uric acid as a component of calcium oxalate stones: diagnostic and therapeutic implications
Article published in Urologia Polska 2002/55/3.

authors

Krzysztof Safranow 1, Piotr Machoy 2
1 Zakład Biochemii i Chemii Pomorskiej Akademii Medycznej w Szczecinie
Kierownik zakładu: dr hab. Dariusz Chlubek
2 Oddział Urologii Samodzielnego Publicznego Zespołu Zakładów Opieki Zdrowotnej w Policach
Kierownik oddziału: dr Piotr Machoy

keywords

urinary tract, urolithiasis, calcium oxalate, uric acid, high-performance liquid chromatography

summary

The role of uric acid (UA) in the pathogenesis of calcium oxalate stones has been published in the literature many times. The aim of the study was to estimate uric acid content in urinary stones which are rich in calcium. We analysed 65 stone samples from 48 patients of the West Pomeranian region of Poland. The uric acid content was examined with the use of highly specific and sensitive high-performance liquid chromatography (HPLC), calcium and magnesium content by atomic absorption method, and phosphorus content by colorimetric method with the use of molybdate. Stones were classified according to the compound present in the highest amount. Uric acid was a principal component in 22% of the stones and was found in 72% of all stones. Calcium oxalate was a principal compound in 50% of the stones. Of calcium oxalate stones, in 33% UA was not found, in 33% there were only <0.1% of UA, and in 33% there were >0.1% of UA. The HPLC purine analysis showed that a majority of calcium oxalate stones contain a trace quantity of UA. These results suggest that UA content in calcium oxalate stones may be useful as an indication for lowering uricosuria in metaphylaxis.

references

  1. 1. Grases F, Costa Bauza A, March JG, Masarova L: Glycosa-minoglycans, uric acid and calcium oxalate urolithiasis. Urol Res 1991; 19: 375-380.
  2. 2. Zieliński J, Kokot F, Borkowski A, Lenko J: Kamica moczowa; w Zieliński J, Lenko J (eds): Urologia, Warszawa, PZWL, 1993, t. 2, str 280-322.
  3. 3. Mandel N: Mechanism of stone formation. Semin Nephrol 1996; 16:364-374.
  4. 4. Leusmann DB: A classification of urinary calculi with respect to their composition and micromorphology. Scand J Urol Nephrol 1991; 25:141-150.
  5. 5. Herring LC: Observations on the analysis often thousand urinary calculi. J Urol 1962; 88: 545-562.
  6. 6. Łącka B, Grzeszczak W, Kowalik K:Patogeneza i leczenie kamicy nerkowej. Wiad Lek 1994; 47: 185-189.
  7. 7. Silcock SR: The role of urate in idiopathic calcium urolithiasis. Adv Exp Med Biol 1980; 122A: 121-127.
  8. 8. Chodorowski Z: Niektóre problemy patofizjologiczne, kliniczne i terapeutyczne zaburzonej przemiany purynowej. Pol Tyg Lek 1982; 37; 1211-1213.
  9. 9. Trzaska Durski Z, Trzaska Durska H, Kuzaka B: Rentgeno-stukturalna analiza fazowa kamieni moczowych. Wyniki badań kamieni zawierających kwas moczowy, moczany i L-cysty-nę. Pol Tyg Lek 1994; 49: 144-146.
  10. 10. Grover PK Ryall RL: Urate and calcium oxalate stones: from repute to rhetoric to reality. Miner Electrolyte Metab 1994; 20: 361-370.
  11. 11. Safranow K: Identyfikacja i oznaczanie pochodnych puryno-wych w kamieniach moczowych jako wskaźników zaburzeń gospodarki purynowej przy zastosowaniu wysokosprawnej chromatografii cieczowej (HPLC). Ann Acad Med Stetin 2000; 46: 35-49.
  12. 12. Safranow K, Machoy Z, Ciechanowski K: Analysis of purines in urinary calculi by high-performance liquid chromatography. Anal Biochem 2000; 286:224-230.
  13. 13. Farrington CJ, Liddy ML, Chalmers AH: A simplified sensitive method for the analysis of renal calculi. Am J Clin Palhol 1980; 73: 96-99.
  14. 14. Daly JA, Ertingshausen G: Direct method for determining inorganic phosphate in serum with the „CentrifiChem\\\". Clin Chem 1972; 18:263-265.
  15. 15. Klohn M, Bolle JR Reverdin NP, Susini A, Baud CA, Gra-ber P: Ammonium urate urinary stones. Urol Res 1986; 14:315-318.
  16. 16. Kleeberg J, Gordon T, Kedar S, Dobler M: Studies on the morphology of human uric acid stones. Urol Res 1981; 9: 259-261.
  17. 17. Machoy P: Analityczna ocena składu mineralnego kamieni moczowych. Rozprawa doktorska PAM, Szczecin, 1993.
  18. 18. Safranow K, Noceń I: Zastosowanie analizy zawartości magnezu w kamieniach moczowych dla oceny patomechanizmu precypitacjipochodnych purynowych. Biul Magnezol 1999; 3: 165-170.
  19. 19. Parks JH., Coward M, Coe FL:Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 1997; 51:894-900.
  20. 20. Sarig S: The hyperuricosuric calcium oxalate stone former. Miner Electrolyte Metab 1987; 13: 251-256.
  21. 21. Ettinger B, Tang A, Citron JT, Livermore B, Williams T: Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986; 315:1386-1389.
  22. 22. Pearle MS, Roehrborn CG, Pak CY:Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 1999; 13:679-685.
  23. 23. Owen-Smith BD: Significance of circadian variations of uric acid elimination. Ann Rheum Dis 1983; 42: 87.
  24. 24. Williams-Larson AW: Urinary calculi associated with purine metabolism. Uric acid nephrolithiasis. Endocrinol Metab Clin North Am 1990; 19: 821-838.
  25. 25. Coe FL: Hyperuricosuric calcium oxalale nephropathy. Kidney Int 1978; 13: 418-426.

correspondence

Knysziof Safranow
Zakład Biochemii i Chemii 1JAM
Al. Powstańców Wielkopolskich 72
70-111 Szczecin
lel/fax: (O-91) 466 15 16
e-mail: chris@mp.pl